CYP19A1
Basic information
Region (hg38): 15:51208057-51338601
Previous symbols: [ "CYP19" ]
Links
Phenotypes
GenCC
Source:
- aromatase excess syndrome (Limited), mode of inheritance: AD
- aromatase excess syndrome (Moderate), mode of inheritance: AD
- aromatase deficiency (Definitive), mode of inheritance: AR
- aromatase deficiency (Supportive), mode of inheritance: AR
- aromatase excess syndrome (Supportive), mode of inheritance: AD
- aromatase deficiency (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Aromatase excess syndrome; Aromatase deficiency | AD/AR | Endocrine | In Aromatase excess syndrome, medical treatment (eg, with aromatase inhibitors) can be beneficial; In Androgen deficiency, females may present with virilization resulting in manifestations such as pseudohermaphroditism, while males may present later with manifestations such as delayed skeletal maturation and epiphyseal closure, skeletal pain, eunuchoid habitus and increased adiposity, and estrogen therapy reverses symptoms | Endocrine | 1825497; 8265607; 9543166; 12736278; 15811932; 17452968; 21521281; 21470988 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (36 variants)
- Aromatase deficiency (4 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CYP19A1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 184 | 192 | ||||
missense | 26 | 41 | ||||
nonsense | 15 | 16 | ||||
start loss | 0 | |||||
frameshift | 19 | 20 | ||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 7 | |||||
splice region | 1 | 28 | 4 | 33 | ||
non coding | 44 | 59 | 38 | 141 | ||
Total | 37 | 11 | 73 | 250 | 47 |
Highest pathogenic variant AF is 0.0000263
Variants in CYP19A1
This is a list of pathogenic ClinVar variants found in the CYP19A1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
15-51208085-T-C | Aromatase deficiency | Benign (Jan 13, 2018) | ||
15-51208162-T-TG | Aromatase deficiency | Uncertain significance (Jun 14, 2016) | ||
15-51208176-A-G | Aromatase deficiency | Likely benign (Jan 12, 2018) | ||
15-51208184-G-A | Aromatase deficiency | Benign (Jan 13, 2018) | ||
15-51208201-T-C | Aromatase deficiency | Uncertain significance (Jan 13, 2018) | ||
15-51208219-G-T | Aromatase deficiency | Uncertain significance (Jan 13, 2018) | ||
15-51208272-G-A | Aromatase deficiency | Uncertain significance (Jan 13, 2018) | ||
15-51208289-A-G | Aromatase deficiency | Uncertain significance (Jan 12, 2018) | ||
15-51208297-C-T | Aromatase deficiency | Benign (Jan 13, 2018) | ||
15-51208311-A-G | Aromatase deficiency | Uncertain significance (Jan 12, 2018) | ||
15-51208341-C-T | Aromatase deficiency | Benign (Jan 13, 2018) | ||
15-51208534-T-C | Aromatase deficiency | Uncertain significance (Jan 13, 2018) | ||
15-51208549-A-AT | Aromatase deficiency | Benign (Jun 14, 2016) | ||
15-51208551-T-C | Aromatase deficiency | Uncertain significance (Jan 13, 2018) | ||
15-51208616-A-G | Aromatase deficiency | Uncertain significance (Jan 13, 2018) | ||
15-51208638-C-T | Aromatase deficiency | Benign (Jan 13, 2018) | ||
15-51208653-A-G | Aromatase deficiency | Uncertain significance (Jan 13, 2018) | ||
15-51208682-C-T | Aromatase deficiency | Uncertain significance (Jan 13, 2018) | ||
15-51208722-C-T | Aromatase deficiency | Uncertain significance (Mar 30, 2018) | ||
15-51208741-A-C | Aromatase deficiency | Uncertain significance (Jan 13, 2018) | ||
15-51208769-C-A | Aromatase deficiency | Benign (Jan 12, 2018) | ||
15-51208776-C-T | Aromatase deficiency | Uncertain significance (Jan 12, 2018) | ||
15-51208919-T-A | Aromatase deficiency | Uncertain significance (Jan 13, 2018) | ||
15-51208920-T-A | Aromatase deficiency | Uncertain significance (Apr 27, 2017) | ||
15-51208920-T-C | Aromatase deficiency | Benign (Jan 13, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CYP19A1 | protein_coding | protein_coding | ENST00000396402 | 9 | 130554 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0000170 | 0.971 | 125723 | 0 | 25 | 125748 | 0.0000994 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.535 | 263 | 289 | 0.911 | 0.0000160 | 3360 |
Missense in Polyphen | 99 | 122.42 | 0.80872 | 1454 | ||
Synonymous | -0.654 | 109 | 101 | 1.08 | 0.00000581 | 928 |
Loss of Function | 1.99 | 11 | 20.8 | 0.530 | 0.00000110 | 258 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000904 | 0.0000904 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000326 | 0.000326 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.0000616 | 0.0000615 |
Middle Eastern | 0.000326 | 0.000326 |
South Asian | 0.000261 | 0.000261 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the formation of aromatic C18 estrogens from C19 androgens.;
- Disease
- DISEASE: Aromatase excess syndrome (AEXS) [MIM:139300]: An autosomal dominant disorder characterized by increased extraglandular aromatization of steroids that presents with heterosexual precocity in males and isosexual precocity in females. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Aromatase deficiency (AROD) [MIM:613546]: A rare disease in which fetal androgens are not converted into estrogens due to placental aromatase deficiency. Thus, pregnant women exhibit a hirsutism, which spontaneously resolves after post-partum. At birth, female babies present with pseudohermaphroditism due to virilization of extern genital organs. In adult females, manifestations include delay of puberty, breast hypoplasia and primary amenorrhoea with multicystic ovaries. {ECO:0000269|PubMed:24705274, ECO:0000269|PubMed:8265607, ECO:0000269|PubMed:8530621, ECO:0000269|PubMed:9211678}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Steroid hormone biosynthesis - Homo sapiens (human);Ovarian steroidogenesis - Homo sapiens (human);Aromatase Inhibitor Pathway (Multiple Tissues), Pharmacodynamics;Estrogen Metabolism Pathway;Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics;17-Beta Hydroxysteroid Dehydrogenase III Deficiency;Androgen and Estrogen Metabolism;Aromatase deficiency;Integrated Breast Cancer Pathway;Follicle Stimulating Hormone (FSH) signaling pathway;Ovarian Infertility Genes;Oxidation by Cytochrome P450;Tryptophan metabolism;Metapathway biotransformation Phase I and II;Phase I - Functionalization of compounds;Metabolism of lipids;Endogenous sterols;Tyrosine metabolism;Androgen and estrogen biosynthesis and metabolism;Cytochrome P450 - arranged by substrate type;Leukotriene metabolism;Biological oxidations;Metabolism;Estrogen biosynthesis;Metabolism of steroid hormones;Metabolism of steroids;Linoleate metabolism;C21-steroid hormone biosynthesis and metabolism;Xenobiotics metabolism;Tryptophan degradation;estradiol biosynthesis II;estradiol biosynthesis I;Arachidonic acid metabolism;superpathway of steroid hormone biosynthesis;Steroid hormones
(Consensus)
Recessive Scores
- pRec
- 0.854
Intolerance Scores
- loftool
- 0.495
- rvis_EVS
- -0.56
- rvis_percentile_EVS
- 19.73
Haploinsufficiency Scores
- pHI
- 0.407
- hipred
- N
- hipred_score
- 0.322
- ghis
- 0.513
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.767
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cyp19a1
- Phenotype
- reproductive system phenotype; normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; pigmentation phenotype; liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; skeleton phenotype; renal/urinary system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; digestive/alimentary phenotype; vision/eye phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); cellular phenotype; homeostasis/metabolism phenotype; muscle phenotype;
Zebrafish Information Network
- Gene name
- cyp19a1a
- Affected structure
- germ line cell
- Phenotype tag
- abnormal
- Phenotype quality
- increased occurrence
Gene ontology
- Biological process
- negative regulation of chronic inflammatory response;steroid biosynthetic process;estrogen biosynthetic process;androgen catabolic process;female gonad development;negative regulation of macrophage chemotaxis;sterol metabolic process;electron transport chain;female genitalia development;mammary gland development;uterus development;prostate gland growth;testosterone biosynthetic process;positive regulation of estradiol secretion
- Cellular component
- endoplasmic reticulum;endoplasmic reticulum membrane;membrane
- Molecular function
- iron ion binding;steroid hydroxylase activity;electron transfer activity;oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen;oxygen binding;heme binding;aromatase activity